Released: February 21, 2019
Defense Health Program
Department of Defense Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2019. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:
- Identify innovative strategies for the screening and early detection of lung cancer.
- Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
- Identify innovative strategies for prevention of the occurrence of lung cancer.
- Identify innovative strategies for the treatment of lung cancer.
- Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
- Develop or optimize predictive markers to assist with therapeutic decision-making.
- Understand mechanisms of resistance to treatment (primary and secondary).
- Understand contributors to lung cancer development other than tobacco.
- Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).
Military Relevance: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:
- Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
- Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
- Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
- Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
- Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Concept Award||Investigators at all academic levels||
|Career Development Award||
|Idea Development Award||
Established Investigators:Independent investigators at or above the level of Assistant Professor (or equivalent); or
New Investigators: Investigators that meet the following criteria at the application submission deadline date:
|Investigator-Initiated Translational Research Award||Independent investigators at or above the level of Assistant Professor (or equivalent)||
|Translational Research Partnership Award||Investigators at or above the level of Assistant Professor (or equivalent)||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Wednesday, February 20, 2019